Dataset Information

Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.

ABSTRACT: Misdirected catalytic activity of histone methyltransferase Dot1L is believed to be causative for a subset of highly aggressive acute leukemias. Targeting the catalytic domain of Dot1L represents a potential therapeutic approach for these leukemias. In the context of a comprehensive Dot1L hit finding strategy, a knowledge-based virtual screen of the Dot1L SAM binding pocket led to the discovery of 2, a non-nucleoside fragment mimicking key interactions of SAM bound to Dot1L. Fragment linking of 2 and 3, an induced back pocket binder identified in earlier studies, followed by careful ligand optimization led to the identification of 7, a highly potent, selective and structurally novel Dot1L inhibitor.

SUBMITTER: Mobitz H

PROVIDER: S-EPMC5346981 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.

Möbitz Henrik H Machauer Rainer R Holzer Philipp P Vaupel Andrea A Stauffer Frédéric F Ragot Christian C Caravatti Giorgio G Scheufler Clemens C Fernandez Cesar C Hommel Ulrich U Tiedt Ralph R Beyer Kim S KS Chen Chao C Zhu Hugh H Gaul Christoph C

ACS medicinal chemistry letters 20170214 3

Misdirected catalytic activity of histone methyltransferase Dot1L is believed to be causative for a subset of highly aggressive acute leukemias. Targeting the catalytic domain of Dot1L represents a potential therapeutic approach for these leukemias. In the context of a comprehensive Dot1L hit finding strategy, a knowledge-based virtual screen of the Dot1L SAM binding pocket led to the discovery of <b>2</b>, a non-nucleoside fragment mimicking key interactions of SAM bound to Dot1L. Fragment link ...[more]

PMID: 28337327

Dataset Information

Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.

Publications

Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.
| S-EPMC4499826 | biostudies-literature

Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.
| S-EPMC4983735 | biostudies-literature

Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping.
| S-EPMC2664101 | biostudies-literature

Discovery of a potent inhibitor of replication protein a protein-protein interactions using a fragment-linking approach.
| S-EPMC3932990 | biostudies-literature

Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.
| S-EPMC4025827 | biostudies-literature

Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.
| S-EPMC5601375 | biostudies-literature

Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2.
| S-EPMC9290007 | biostudies-literature

Discovery of a Novel Series of Potent and Selective Alkynylthiazole-Derived PI3Kγ Inhibitors.
| S-EPMC7812679 | biostudies-literature

Fragment-Based Discovery of Novel MUS81 Inhibitors.
| S-EPMC11247637 | biostudies-literature

Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket.
| S-EPMC4983739 | biostudies-literature